AGIO

Agios Pharmaceuticals (AGIO) is the lead sponsor of 11 active clinical trials listed on ClinicalTrials.gov^[5], including 5 Phase 3^[1], 4 Phase 2^[2], 1 Phase 1^[3], 1 Phase 4^[4].

Trial NCT05144256^[6] evaluates Mitapivat in Pediatric Pyruvate Kinase Deficiency with a target enrollment of 49 participants. Trial NCT04770779^[7] evaluates Placebo Matching Mitapivat in Transfusion-dependent Alpha-Thalassemia with a target enrollment of 258 participants. Trial NCT05031780^[8] evaluates Mitapivat in Sickle Cell Disease with a target enrollment of 286 participants.

AGIO has 6 Form 4 insider filings recorded at the SEC in the past 30 days^[9].